Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1D | P48730 | 5/20 | 0.46 |
| ▸ | CSNK1G2 | P78368 | 4/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 3/20 | 0.46 |
| ▸ | GSK3B | P49841 | 3/20 | 0.46 |
| ▸ | CFB | P00751 | 6/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.41 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.41 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL803692 | 0.87 | CSNK1D (0.59) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL15625905 | 0.84 | MAPK10 (0.44) | CSNK1DCSNK1G2CSNK1A1GSK3BCFB | |
| SCHEMBL7655142 | 0.84 | NPSR1 (0.53) | CFBL3MBTL1ALDH1A1SMN1; SMN2IMPDH2 | |
| SCHEMBL1794997 | 0.78 | CSNK1D (0.47) | CSNK1DCSNK1G2CSNK1A1GSK3BALDH1A1 | |
| SCHEMBL23619188 | 0.78 | ALDH1A1 (0.47) | L3MBTL1ALDH1A1SMN1; SMN2 | |
| SCHEMBL21705379 | 0.77 | HDAC6 (0.59) | CSNK1DCSNK1G2CSNK1A1GSK3B | |
| SCHEMBL31027982 | 0.77 | HDAC6 (0.59) | CSNK1DCSNK1G2CSNK1A1GSK3B | |
| SCHEMBL4387879 | 0.76 | IMPDH2 (0.46) | CSNK1DCSNK1G2CSNK1A1GSK3BIMPDH2 | |
| SCHEMBL10005347 | 0.76 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1SMN1; SMN2PIN1 | |
| SCHEMBL846855 | 0.76 | SCN10A (0.58) | L3MBTL1ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3675858-B1 | IMIDAZO[1,5-A]PYRAZINE COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | OPTIKIRA LLC (US) | 2023-04-26 | — | — | EP | disclosed |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS INC (US) | 2022-04-21 | — | — | US | disclosed |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2022-02-15 | — | — | US | disclosed |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-11-12 | — | — | US | disclosed |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | BRISTOL MYERS SQUIBB CO (US) | 2020-07-23 | — | — | US | disclosed |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2020-05-28 | — | — | US | disclosed |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2019-05-09 | — | — | US | disclosed |
| US-20090264405-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-10-22 | — | — | US | disclosed |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-14 | — | — | US | disclosed |
| US-7217720-B2 | 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264405-A1 | Cetp Inhibitors | CETP, APOB, PCSK9 | CSNK1D 722/4885CSNK1G2 1098/4885CSNK1A1 664/4885 |
| US-20200354367-A1 | COMPOUNDS AND COMPOSITIONS FOR IRE1 INHIBITION | XBP1, RNASE1, ERN1 | CSNK1D 4212/4885CSNK1G2 3300/4885CSNK1A1 3200/4885 |
| US-20070135467-A1 | HETEROCYCLIC CETP INHIBITORS | CETP, CES1, NPC1 | CSNK1D 616/4885CSNK1G2 911/4885CSNK1A1 588/4885 |
| US-11248000-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | CSNK1D 3021/4885CSNK1G2 2659/4885CSNK1A1 2733/4885 |
| US-20220119400-A1 | QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS | CFB, TFPI, MAOB | CSNK1D 3021/4885CSNK1G2 2659/4885CSNK1A1 2733/4885 |
| US-10961252-B2 | Quinazoline and indole compounds to treat medical disorders | CFB, TFPI, MAOB | CSNK1D 3021/4885CSNK1G2 2659/4885CSNK1A1 2733/4885 |
| US-20200231547-A1 | 2-(1,1'-BIPHENYL)-1H-BENZODIMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES | APLNR, AP3B1, AP2B1 | CSNK1D 1270/4885CSNK1G2 930/4885CSNK1A1 1257/4885 |
| US-20200165262-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | CSNK1D 3021/4885CSNK1G2 2659/4885CSNK1A1 2733/4885 |
| US-20190135825-A1 | Quinazoline and Indole Compounds to Treat Medical Disorders | CFB, TFPI, MAOB | CSNK1D 3021/4885CSNK1G2 2659/4885CSNK1A1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.